Lupin expects biosimilars, injectables to pilot medium-term growth

Lupin Ltd expects biosimilars and injectable drugs to be major growth drives in the medium-term, and hopes to earn $300 mln in sales of biosimilars within the next four to five years, the company said at a recent virtual conference by Kotak Institutional Equities. The company is also working on various complex injectable products including peptides and expects this segment to become a $250-mln business during the same time.